Information Request

Virology



Zika and Dengue Viruses

Dengue and Zika Reporter Viruses

Flavivirus Reporter Virus Particles (RVPs) are replication-incompetent viruses that enable viral infectivity, neutralization, and enhancement studies to be conducted safely, easily, and reproducibly using standard detection instrumentation. RVPs are antigenically identical to wild-type viruses since they incorporate virus-specific prM/E proteins, but they contain a modified RNA genome. RVPs express convenient optical reporter genes upon cellular infection and are offered as quality-controlled, ready-to-use reagents. RVPs are an efficient alternative to plaque assays, and have been adopted by dozens of commercial and academic Flavivirus laboratories.


See RVP application notes



Epitope Mapping on Viral Targets

Epitope Mapping on Viral Targets

The epitopes of antibodies that target viral envelopes are mapped at single amino acid resolution using Shotgun Mutagenesis. Mutations (e.g. Alanine) are systematically introduced at every amino acid in a target protein and individually tested for MAb reactivity in human cells. This approach is successful for mapping neutralizing or non-neutralizing MAbs which recognize conformational or linear epitopes. To date, Integral Molecular has epitope mapped over 500 MAbs for therapeutic, vaccine, and research studies. Applications include intellectual property protection, determining neutralizing structures, mapping immune responses to pathogens or vaccines, and optimizing MAb cocktail therapies.


Pre-validated libraries for select viral envelopes are available for expedited project turnaround time.



Protein Engineering for Vaccine Discovery

Protein Engineering for Vaccine Discovery

Viral envelope functions including infectivity, budding, and protein folding can be ascribed to individual amino acids or regions by functional screening of mutation libraries. Comprehensive and combinatorial mutagenesis strategies (point mutations and/or chimeras) are used to identify vaccine variants with desired characteristics, such as improved expression, budding, stability, antigenicity, infectivity, or manufacturing properties.



Antibody Discovery against Viral Targets

Antibody Discovery against Viral Targets

The MPS Discovery Engine® enables the isolation and optimization of antibodies against the most challenging viral targets. The platform harnesses the strength of Integral Molecular's 15+ years of membrane protein expertise and proprietary technologies including Lipoparticle antigen presentation, DNA+Lipoparticle immunization, and microfluidic B-cell cloning.


Virus

RVPs

Pre-validated Libraries

MAbs

Dengue Virus 1

prM/E

prM/E

Dengue Virus 2

prM/E

prM/E

Dengue Virus 3

prM/E

prM/E

Dengue Virus 4

prM/E

prM/E

Zika Virus

prM/E

prM/E

Ebola Virus

GP

Chikungunya Virus

E2/E1

HIV

gp160

Hepatitis C Virus

E1/E2

coming soon

Hepatitis B Virus

sAg

Respiratory Syncitial Virus

F protein

Contact us for custom services



  • Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.
  • Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.
  • Atomic-level functional model of dengue virus Envelope protein infectivity.
  • Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.
  • Exposure of Epitope Residues on the Outer Face of the Chikungunya Virus Envelope Trimer Determines Antibody Neutralizing Efficacy.
  • Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.